** Shares of drugmaker Bristol Myers Squibb BMY.N up 3.2% at $57.61
** Co says the U.S. FDA has accepted for review its marketing application seeking approval of the combination of BMY's Opdivo plus Yervoy as a potential first-line treatment option for patients with types of colorectal cancer
** The FDA is set to make a decision by June 23
** Opdivo plus Yervoy is already approved to treat cancers of the skin, lung, kidney, colon and esophagus
** BMY has rose ~10% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.